AR048342A1 - FORMAS DE DOSIFICACIoN FARMACÉUTICAS QUE COMPRENDEN EL ÁCIDO N-(2-(2-FTALIMIDOETOXI)-ACETIL)-L-ALANIL-D-GLUTÁMICO (LK-423) - Google Patents

FORMAS DE DOSIFICACIoN FARMACÉUTICAS QUE COMPRENDEN EL ÁCIDO N-(2-(2-FTALIMIDOETOXI)-ACETIL)-L-ALANIL-D-GLUTÁMICO (LK-423)

Info

Publication number
AR048342A1
AR048342A1 ARP050101197A ARP050101197A AR048342A1 AR 048342 A1 AR048342 A1 AR 048342A1 AR P050101197 A ARP050101197 A AR P050101197A AR P050101197 A ARP050101197 A AR P050101197A AR 048342 A1 AR048342 A1 AR 048342A1
Authority
AR
Argentina
Prior art keywords
dosage forms
pharmaceutical dosage
glutamic acid
fthalimidoetoxi
acetile
Prior art date
Application number
ARP050101197A
Other languages
English (en)
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Publication of AR048342A1 publication Critical patent/AR048342A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente se refiere a formas de dosificacion farmacéuticas que hacen posible el suministro controlado y/o dirigido de una sustancia activa a regiones seleccionadas del tracto gastrointestinal de seres humanos o animales. Las formas de dosificacion farmacéuticas comprenden a la sustancia activa de ácido N-(2-(2-ftalimido-etoxi)-acetil)-L-alanil-D-glutámico (designado como LK 423). Se dan a conocer métodos de tratamiento de enfermedades inflamatorias cronicas del tracto gastrointestinal de seres humanos y/o animales, mediante el uso de dichas formas de dosificacion farmacéuticas. Proceso para la preparacion de dichas formas de dosificacion farmacéuticas.
ARP050101197A 2004-03-26 2005-03-28 FORMAS DE DOSIFICACIoN FARMACÉUTICAS QUE COMPRENDEN EL ÁCIDO N-(2-(2-FTALIMIDOETOXI)-ACETIL)-L-ALANIL-D-GLUTÁMICO (LK-423) AR048342A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SI200400094 2004-03-26

Publications (1)

Publication Number Publication Date
AR048342A1 true AR048342A1 (es) 2006-04-19

Family

ID=34964906

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101197A AR048342A1 (es) 2004-03-26 2005-03-28 FORMAS DE DOSIFICACIoN FARMACÉUTICAS QUE COMPRENDEN EL ÁCIDO N-(2-(2-FTALIMIDOETOXI)-ACETIL)-L-ALANIL-D-GLUTÁMICO (LK-423)

Country Status (15)

Country Link
US (1) US20100183714A1 (es)
EP (1) EP1734933B1 (es)
JP (1) JP2007530492A (es)
CN (1) CN1956707B (es)
AR (1) AR048342A1 (es)
AT (1) ATE468846T1 (es)
AU (1) AU2005226927B2 (es)
BR (1) BRPI0509271A (es)
CA (1) CA2559685A1 (es)
DE (1) DE602005021475D1 (es)
MY (1) MY145329A (es)
PE (1) PE20051163A1 (es)
RU (1) RU2375047C2 (es)
TW (1) TW200600121A (es)
WO (1) WO2005092295A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273376B2 (en) 2006-11-17 2012-09-25 Da Volterra Colonic delivery of metallo-dependent enzymes
CN101795675A (zh) * 2006-11-17 2010-08-04 达沃尔泰拉公司 使用具有Eudragit包衣的Zn/果胶珠粒进行的结肠递送
US20100239682A1 (en) * 2007-09-17 2010-09-23 Antoine Andremont Colonic delivery of antimicrobial agents
HUE032368T2 (en) * 2008-11-13 2017-09-28 Nogra Pharma Ltd Antisense preparations and methods for their preparation and application
ES2898930T3 (es) * 2015-06-01 2022-03-09 Xeno Biosciences Inc Composiciones para usar en la modulación de la microbiota intestinal y el manejo del peso
WO2017223337A1 (en) * 2016-06-23 2017-12-28 Nutrivert Llc Methods to promote growth and improve feed conversion in animals
AU2017356350B2 (en) * 2016-11-09 2024-02-29 Engene, Inc. Intestinal expression of programmed death ligand 1
MX2019006821A (es) 2016-12-14 2019-10-21 Progenity Inc Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de cinasa de janus (jak) y dispositivos.
CN116712540A (zh) * 2016-12-14 2023-09-08 比奥拉治疗股份有限公司 使用整联蛋白抑制剂治疗胃肠道疾病
CA3045307A1 (en) * 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
CN108968074B (zh) * 2018-06-06 2021-09-28 福建省农业科学院农业工程技术研究所 一种结肠靶向递送的银耳糖醛酸多糖-芙蓉李花青素复合物及其制备方法
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2773959B2 (ja) * 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
YU183090A (sh) * 1990-09-27 1992-12-21 Lek Novi n-acildipeptidi, postopki za njihovo pripravo in farmacevtski pripravki, kojih vsebujejo
DE19732903A1 (de) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems

Also Published As

Publication number Publication date
EP1734933A1 (en) 2006-12-27
TW200600121A (en) 2006-01-01
EP1734933B1 (en) 2010-05-26
CN1956707B (zh) 2010-12-29
PE20051163A1 (es) 2006-02-21
RU2375047C2 (ru) 2009-12-10
ATE468846T1 (de) 2010-06-15
MY145329A (en) 2012-01-31
AU2005226927A1 (en) 2005-10-06
DE602005021475D1 (de) 2010-07-08
WO2005092295A1 (en) 2005-10-06
JP2007530492A (ja) 2007-11-01
CN1956707A (zh) 2007-05-02
US20100183714A1 (en) 2010-07-22
CA2559685A1 (en) 2005-10-06
BRPI0509271A (pt) 2007-09-04
AU2005226927B2 (en) 2010-09-23
RU2006137660A (ru) 2008-05-10

Similar Documents

Publication Publication Date Title
AR048342A1 (es) FORMAS DE DOSIFICACIoN FARMACÉUTICAS QUE COMPRENDEN EL ÁCIDO N-(2-(2-FTALIMIDOETOXI)-ACETIL)-L-ALANIL-D-GLUTÁMICO (LK-423)
UY30587A1 (es) Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasa s janus
CY1123162T1 (el) Ελεγχομενης αποδεσμευσης φαρμακευτικα σκευασματα νιταζοξανιδης
AR058679A1 (es) Preparacion farmaceutica que contiene meloxicam
ES2496892T3 (es) Formulaciones para el tratamiento de trastornos del tracto respiratorio superior
WO2008157103A3 (en) Modified release solid or semi-solid dosage forms
UY29321A1 (es) Piperazinilureas y piperidinilureas como moduladores de hidrolasa de amida de ácidos grasos
EA200800360A1 (ru) Формуляции с высоким содержанием лекарства и дозированные формы
BRPI0924460A2 (pt) composição farmacêutica para uso em oftalmologia médica e veterinária
AR048718A1 (es) Uso de formulaciones de meloxicam en medicina veterinaria
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
EA200970374A1 (ru) Лечение антиаритмическими средствами и омега-3 жирными кислотами и их комбинированным продуктом
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
DE602007004093D1 (de) 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren
CL2009001077A1 (es) Vehiculo particulado polimerico que comprende un agente biologico en fase acuosa en un lumen hueco; procedimiento para suministrar una proteina en el ojo; composicion farmaceutica que comprende dicho vehiculo; y su uso para profilaxis y tratar enfermedades o trastornos del ojo.
WO2011151722A3 (en) Methods and compositions for oral pharmaceutical therapy
CY1116840T1 (el) Χρηση 24-norudca
AR045783A1 (es) Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide
CR7049A (es) Empleo de flumazenilo en la elaboracion de una medicacion para el tratamiento de la dependencia del alcohol
AR053285A1 (es) Tratamiento de enfemedades usando un sistema mejorado de expresion regulada
EA200900269A1 (ru) Лекарственные комбинации для лечения заболеваний дыхательных путей
CL2008001766A1 (es) Forma cristalina a y b de 3-(2r-tetrahidrofuril-metil)-2-tioxantina; inhibidor de mieloperoxidasa; procesos para su preparación; formulación farmacéutica que las comprende; y uso en el tratamiento de trastornos neuroinflamatorios,trastornos ateroscleroticos cardio y cerebrovasculares, insuficiencia cardiaca, bronquitis.
ATE546159T1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen enthaltend langwirksame beta-2-agonisten und wenigstens einen weiteren wirkstoff
CL2019002145A1 (es) Composición farmacéutica que comprende betahistina.
DE602004017164D1 (de) Albuminkonjugate, die eine Glucuron-Verknüpfung enthalten

Legal Events

Date Code Title Description
FB Suspension of granting procedure